BAFNA PHARMACEUTICALS LTD Financial Ratios
BAFNAPH · Healthcare · Current price ₹225.88
P/E ratio
129.1x
P/B ratio
5.0x
ROE
-3.7%
ROCE
8.0%
Debt / Equity
0.39
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 129.1x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 5.0x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | -3.7% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 8.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.39 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with BAFNA PHARMACEUTICALS LTD's latest numbers.
BAFNA PHARMACEUTICALS LTD profitability
BAFNA PHARMACEUTICALS LTD generates a return on equity of -3.7% and a return on capital employed of 8.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.39 and a P/E of 129.1x, BAFNA PHARMACEUTICALS LTD is conservatively financed. Our overall business-quality score for the company is 2.5 / 10.
Understand the ratios
More on BAFNA PHARMACEUTICALS LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.